Capstone Therapeutics, Inc. – “Following the Data”

NEW YORK, NY / ACCESSWIRE / April 27, 2015 / Capstone Therapeutics (OTCQB:CAPS) today published a new blog post on The Chairman’s Blog, written by the Company’s Executive Chairman and CEO, Jock Holliman, and President of LipimetiX Development, LLC, Dennis I. Goldberg, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

The latest blog discusses how further examining data from the Phase 1b/2a human clinical trials led Capstone and its joint development partner, LipimetiX Development, LLC, to prioritize acute pancreatitis (AP) with high triglycerides as the indication of choice for AEM-28 commercialization. “We believe we have found a special opportunity in AP, with a clear unmet need, and are quite excited to pursue this indication with our new composition of matter, 21-year commercial life molecule, AEM-28-02.” Read the full blog post on TheChairmansBlog.com (http://www.thechairmansblog.com/capstone-therapeutics/john-holliman/following-data/).

About Capstone Therapeutics

Capstone Therapeutics is a biotechnology company committed to developing novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is focused on development and commercialization of Apo E Mimetic Peptide Molecule AEM-28 and its analogs (through the LipimetiX Development, LLC, joint venture).

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com

ReleaseID: 428198